Exendin-4 protects oxidative stress-induced β-cell apoptosis through reduced JNK and GSK3β activity
- PMID: 21060752
- PMCID: PMC2967000
- DOI: 10.3346/jkms.2010.25.11.1626
Exendin-4 protects oxidative stress-induced β-cell apoptosis through reduced JNK and GSK3β activity
Abstract
Oxidative stress induced by chronic hyperglycemia in type 2 diabetes plays a crucial role in progressive loss of β-cell mass through β-cell apoptosis. Glucagon like peptide-1 (GLP-1) has effects on preservation of β-cell mass and its insulin secretory function. GLP-1 possibly increases islet cell mass through stimulated proliferation from β-cell and differentiation to β-cell from progenitor cells. Also, it probably has an antiapoptotic effect on β-cell, but detailed mechanisms are not proven. Therefore, we examined the protective mechanism of GLP-1 in β-cell after induction of oxidative stress. The cell apoptosis decreased to ~50% when cells were treated with 100 µM H(2)O(2) for up to 2 hr. After pretreatment of Ex-4, GLP-1 receptor agonist, flow cytometric analysis shows 41.7% reduction of β-cell apoptosis. This data suggested that pretreatment of Ex-4 protect from oxidative stress-induced apoptosis. Also, Ex-4 treatment decreased GSK3β activation, JNK phosphorylation and caspase-9, -3 activation and recovered the expression of insulin2 mRNA in β-cell lines and secretion of insulin in human islet. These results suggest that Ex-4 may protect β-cell apoptosis by blocking the JNK and GSK3β mediated apoptotic pathway.
Keywords: Apoptosis; Exendin-4; Glucagon-Like Peptide 1; Insulin-Secreting Cells; Oxidative Stress.
Figures




Similar articles
-
Exendin-4, a glucagon-like peptide-1 receptor agonist, inhibits cell apoptosis induced by lipotoxicity in pancreatic β-cell line.Peptides. 2012 Sep;37(1):18-24. doi: 10.1016/j.peptides.2012.06.018. Epub 2012 Jul 7. Peptides. 2012. PMID: 22776329
-
Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis.J Biol Chem. 2003 Jan 3;278(1):471-8. doi: 10.1074/jbc.M209423200. Epub 2002 Oct 29. J Biol Chem. 2003. PMID: 12409292
-
Glucagon-like peptide-1 activation of TCF7L2-dependent Wnt signaling enhances pancreatic beta cell proliferation.J Biol Chem. 2008 Mar 28;283(13):8723-35. doi: 10.1074/jbc.M706105200. Epub 2008 Jan 23. J Biol Chem. 2008. PMID: 18216022 Free PMC article.
-
Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes.Regul Pept. 2004 Feb 15;117(2):77-88. doi: 10.1016/j.regpep.2003.10.028. Regul Pept. 2004. PMID: 14700743 Review.
-
Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors.Expert Opin Emerg Drugs. 2004 May;9(1):155-66. doi: 10.1517/eoed.9.1.155.32952. Expert Opin Emerg Drugs. 2004. PMID: 15155141 Review.
Cited by
-
Exendin-4 pretreated adipose derived stem cells are resistant to oxidative stress and improve cardiac performance via enhanced adhesion in the infarcted heart.PLoS One. 2014 Jun 10;9(6):e99756. doi: 10.1371/journal.pone.0099756. eCollection 2014. PLoS One. 2014. PMID: 24915574 Free PMC article.
-
Differential protective effects of exenatide, an agonist of GLP-1 receptor and Piragliatin, a glucokinase activator in beta cell response to streptozotocin-induced and endoplasmic reticulum stresses.PLoS One. 2013 Sep 19;8(9):e73340. doi: 10.1371/journal.pone.0073340. eCollection 2013. PLoS One. 2013. PMID: 24069189 Free PMC article.
-
Incretin Mimetics as Rational Candidates for the Treatment of Traumatic Brain Injury.ACS Pharmacol Transl Sci. 2019 Apr 12;2(2):66-91. doi: 10.1021/acsptsci.9b00003. Epub 2019 Feb 11. ACS Pharmacol Transl Sci. 2019. PMID: 31396586 Free PMC article.
-
Network analysis combined with experimental assessment to explore the therapeutic mechanisms of New Shenqi Pills formula targeting mitochondria on senile diabetes mellitus.Front Pharmacol. 2024 Jun 12;15:1339758. doi: 10.3389/fphar.2024.1339758. eCollection 2024. Front Pharmacol. 2024. PMID: 38948458 Free PMC article.
-
Glucagon-like peptide-1 enhances cardiac L-type Ca2+ currents via activation of the cAMP-dependent protein kinase A pathway.Cardiovasc Diabetol. 2011 Jan 20;10:6. doi: 10.1186/1475-2840-10-6. Cardiovasc Diabetol. 2011. PMID: 21251280 Free PMC article.
References
-
- Jonas JC, Sharma A, Hasenkamp W, Ilkova H, Patanè G, Laybutt R, Bonner-Weir S, Weir GC. Chronic hyperglycemia triggers loss of pancreatic beta cell differentiation in an animal model of diabetes. J Biol Chem. 1999;274:14112–14121. - PubMed
-
- Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813–820. - PubMed
-
- Evans JL, Goldfine ID, Maddux BA, Grodsky GM. Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev. 2002;23:599–622. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous